Newron Pharmaceuticals S.p.A. announced changes in its management team with the departure of Luca Benatti, CEO, effective as of May 31, 2012. Luca Benatti, founder and CEO since 1999, will leave the company to pursue other opportunities, having overseen the completion of the Phase III program for safinamide and a new partnership, also announced on May 14, 2012, with Zambon. As a result of Dr. Benatti's decision to leave Newron, the new management team will be comprised of Stefan Weber, CEO and member of the Board of Directors, who has been company's CFO since 2005; Ravi Anand, MD, its Chief Medical Officer since 2005, Marco Caremi, Executive Vice President Business Development, and Roberto Galli, Vice President Finance, both with the company since 2002. Rolf Stahel, Patrick Langlois, Francesco Parenti, Hanns Moehler and Stefan Weber will serve on company's Board of Directors.